Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Awad, MM; Gadgeel, SM; Borghaei, H; Patnaik, A; Yang, JCH; Powell, SF; Gentzler, RD; Martins, RG; Stevenson, JP; Altan, M; Jalal, SI; Panwalkar, A; Gubens, M; Sequist, LV; Saraf, S; Zhao, B; Piperdi, B; Langer, CJ

Awad, MM (corresponding author), Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Med Oncol, 450 Brookline Ave,Dana 1240G, Boston, MA 02115 USA.

JOURNAL OF THORACIC ONCOLOGY, 2021; 16 (1): 162

Abstract

Introduction: In cohort G of KEYNOTE-021 (NCT02039674), first-line pembrolizumab plus pemetrexed-carboplatin significantly improved the objective resp......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索